US20190365998A1 - Autoinjector - Google Patents
Autoinjector Download PDFInfo
- Publication number
- US20190365998A1 US20190365998A1 US16/542,964 US201916542964A US2019365998A1 US 20190365998 A1 US20190365998 A1 US 20190365998A1 US 201916542964 A US201916542964 A US 201916542964A US 2019365998 A1 US2019365998 A1 US 2019365998A1
- Authority
- US
- United States
- Prior art keywords
- autoinjector
- syringe
- plunger
- medicament
- processing unit
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 229940090047 auto-injector Drugs 0.000 title claims abstract description 92
- 239000007924 injection Substances 0.000 claims description 62
- 238000002347 injection Methods 0.000 claims description 62
- 239000003814 drug Substances 0.000 claims description 37
- 238000012545 processing Methods 0.000 claims description 21
- 238000013500 data storage Methods 0.000 claims description 9
- 230000000007 visual effect Effects 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 7
- 230000008569 process Effects 0.000 claims description 6
- 230000003287 optical effect Effects 0.000 claims description 5
- JUFFVKRROAPVBI-PVOYSMBESA-N chembl1210015 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N[C@H]1[C@@H]([C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@]3(O[C@@H](C[C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C3)C(O)=O)O2)O)[C@@H](CO)O1)NC(C)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 JUFFVKRROAPVBI-PVOYSMBESA-N 0.000 description 54
- 108010011459 Exenatide Proteins 0.000 description 50
- 229960001519 exenatide Drugs 0.000 description 50
- 101000976075 Homo sapiens Insulin Proteins 0.000 description 22
- QEFRNWWLZKMPFJ-YGVKFDHGSA-N L-methionine S-oxide Chemical compound CS(=O)CC[C@H](N)C(O)=O QEFRNWWLZKMPFJ-YGVKFDHGSA-N 0.000 description 22
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 21
- 230000007246 mechanism Effects 0.000 description 11
- 239000012634 fragment Substances 0.000 description 10
- 235000001014 amino acid Nutrition 0.000 description 9
- 150000001413 amino acids Chemical class 0.000 description 9
- 239000007788 liquid Substances 0.000 description 8
- 150000003839 salts Chemical class 0.000 description 8
- 239000000427 antigen Substances 0.000 description 7
- 102000036639 antigens Human genes 0.000 description 7
- 108091007433 antigens Proteins 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 238000003780 insertion Methods 0.000 description 6
- 230000037431 insertion Effects 0.000 description 6
- 229940079593 drug Drugs 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 108060003951 Immunoglobulin Proteins 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 102000018358 immunoglobulin Human genes 0.000 description 4
- 230000007704 transition Effects 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical class N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 3
- 239000003055 low molecular weight heparin Substances 0.000 description 3
- 229940127215 low-molecular weight heparin Drugs 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 231100000241 scar Toxicity 0.000 description 3
- 208000004476 Acute Coronary Syndrome Diseases 0.000 description 2
- 208000032544 Cicatrix Diseases 0.000 description 2
- 208000002249 Diabetes Complications Diseases 0.000 description 2
- 206010012689 Diabetic retinopathy Diseases 0.000 description 2
- 108010088406 Glucagon-Like Peptides Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000001447 alkali salts Chemical class 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- LMHMJYMCGJNXRS-IOPUOMRJSA-N exendin-3 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@H](C)O)[C@H](C)O)C(C)C)C1=CC=CC=C1 LMHMJYMCGJNXRS-IOPUOMRJSA-N 0.000 description 2
- 238000005286 illumination Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 230000037387 scars Effects 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- 125000001831 (C6-C10) heteroaryl group Chemical group 0.000 description 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010037003 Buserelin Proteins 0.000 description 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
- 125000000041 C6-C10 aryl group Chemical group 0.000 description 1
- 108010000437 Deamino Arginine Vasopressin Proteins 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 1
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102400000932 Gonadoliberin-1 Human genes 0.000 description 1
- 108010069236 Goserelin Proteins 0.000 description 1
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101500026183 Homo sapiens Gonadoliberin-1 Proteins 0.000 description 1
- 102000002265 Human Growth Hormone Human genes 0.000 description 1
- 108010000521 Human Growth Hormone Proteins 0.000 description 1
- 239000000854 Human Growth Hormone Substances 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 1
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- HBBGRARXTFLTSG-UHFFFAOYSA-N Lithium ion Chemical compound [Li+] HBBGRARXTFLTSG-UHFFFAOYSA-N 0.000 description 1
- XVVOERDUTLJJHN-UHFFFAOYSA-N Lixisenatide Chemical compound C=1NC2=CC=CC=C2C=1CC(C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)NC(CC(N)=O)C(=O)NCC(=O)NCC(=O)N1C(CCC1)C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N1C(CCC1)C(=O)N1C(CCC1)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)CC)NC(=O)C(NC(=O)C(CC(C)C)NC(=O)C(CCCNC(N)=N)NC(=O)C(NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(CCC(O)=O)NC(=O)C(CCC(O)=O)NC(=O)C(CCSC)NC(=O)C(CCC(N)=O)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(CC(O)=O)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC=1C=CC=CC=1)NC(=O)C(NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)CNC(=O)C(N)CC=1NC=NC=1)C(C)O)C(C)O)C(C)C)CC1=CC=CC=C1 XVVOERDUTLJJHN-UHFFFAOYSA-N 0.000 description 1
- 102000009151 Luteinizing Hormone Human genes 0.000 description 1
- 108010073521 Luteinizing Hormone Proteins 0.000 description 1
- 108010021717 Nafarelin Proteins 0.000 description 1
- 208000012266 Needlestick injury Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- 108010010056 Terlipressin Proteins 0.000 description 1
- 208000001435 Thromboembolism Diseases 0.000 description 1
- 108010050144 Triptorelin Pamoate Proteins 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 229960002719 buserelin Drugs 0.000 description 1
- CUWODFFVMXJOKD-UVLQAERKSA-N buserelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 CUWODFFVMXJOKD-UVLQAERKSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 229960004281 desmopressin Drugs 0.000 description 1
- NFLWUMRGJYTJIN-NXBWRCJVSA-N desmopressin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSCCC(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(N)=O)=O)CCC(=O)N)C1=CC=CC=C1 NFLWUMRGJYTJIN-NXBWRCJVSA-N 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960005153 enoxaparin sodium Drugs 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 108010015174 exendin 3 Proteins 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229960001442 gonadorelin Drugs 0.000 description 1
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 1
- 229960002913 goserelin Drugs 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 239000000960 hypophysis hormone Substances 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 239000004026 insulin derivative Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- 229910001416 lithium ion Inorganic materials 0.000 description 1
- XVVOERDUTLJJHN-IAEQDCLQSA-N lixisenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 XVVOERDUTLJJHN-IAEQDCLQSA-N 0.000 description 1
- 108010004367 lixisenatide Proteins 0.000 description 1
- 229960001093 lixisenatide Drugs 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 238000003032 molecular docking Methods 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- RWHUEXWOYVBUCI-ITQXDASVSA-N nafarelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 RWHUEXWOYVBUCI-ITQXDASVSA-N 0.000 description 1
- 229960002333 nafarelin Drugs 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 229960004532 somatropin Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 241001223854 teleost fish Species 0.000 description 1
- 229960003813 terlipressin Drugs 0.000 description 1
- BENFXAYNYRLAIU-QSVFAHTRSA-N terlipressin Chemical compound NCCCC[C@@H](C(=O)NCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)CN)CSSC1 BENFXAYNYRLAIU-QSVFAHTRSA-N 0.000 description 1
- CIJQTPFWFXOSEO-NDMITSJXSA-J tetrasodium;(2r,3r,4s)-2-[(2r,3s,4r,5r,6s)-5-acetamido-6-[(1r,2r,3r,4r)-4-[(2r,3s,4r,5r,6r)-5-acetamido-6-[(4r,5r,6r)-2-carboxylato-4,5-dihydroxy-6-[[(1r,3r,4r,5r)-3-hydroxy-4-(sulfonatoamino)-6,8-dioxabicyclo[3.2.1]octan-2-yl]oxy]oxan-3-yl]oxy-2-(hydroxy Chemical compound [Na+].[Na+].[Na+].[Na+].O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1O)NC(C)=O)O[C@@H]1C(C[C@H]([C@@H]([C@H]1O)O)O[C@@H]1[C@@H](CO)O[C@H](OC2C(O[C@@H](OC3[C@@H]([C@@H](NS([O-])(=O)=O)[C@@H]4OC[C@H]3O4)O)[C@H](O)[C@H]2O)C([O-])=O)[C@H](NC(C)=O)[C@H]1C)C([O-])=O)[C@@H]1OC(C([O-])=O)=C[C@H](O)[C@H]1O CIJQTPFWFXOSEO-NDMITSJXSA-J 0.000 description 1
- 229960004824 triptorelin Drugs 0.000 description 1
- VXKHXGOKWPXYNA-PGBVPBMZSA-N triptorelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 VXKHXGOKWPXYNA-PGBVPBMZSA-N 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/28—Syringe ampoules or carpules, i.e. ampoules or carpules provided with a needle
- A61M5/281—Syringe ampoules or carpules, i.e. ampoules or carpules provided with a needle using emptying means to expel or eject media, e.g. pistons, deformation of the ampoule, or telescoping of the ampoule
- A61M5/283—Syringe ampoules or carpules, i.e. ampoules or carpules provided with a needle using emptying means to expel or eject media, e.g. pistons, deformation of the ampoule, or telescoping of the ampoule by telescoping of ampoules or carpules with the syringe body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/32—Needles; Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
- A61M5/3202—Devices for protection of the needle before use, e.g. caps
- A61M5/3204—Needle cap remover, i.e. devices to dislodge protection cover from needle or needle hub, e.g. deshielding devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/42—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests having means for desensitising skin, for protruding skin to facilitate piercing, or for locating point where body is to be pierced
- A61M5/427—Locating point where body is to be pierced, e.g. vein location means using ultrasonic waves, injection site templates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/50—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests having means for preventing re-use, or for indicating if defective, used, tampered with or unsterile
- A61M5/5086—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests having means for preventing re-use, or for indicating if defective, used, tampered with or unsterile for indicating if defective, used, tampered with or unsterile
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
- A61M2005/206—With automatic needle insertion
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
- A61M2005/2073—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically preventing premature release, e.g. by making use of a safety lock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
- A61M2005/2073—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically preventing premature release, e.g. by making use of a safety lock
- A61M2005/208—Release is possible only when device is pushed against the skin, e.g. using a trigger which is blocked or inactive when the device is not pushed against the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/24—Ampoule syringes, i.e. syringes with needle for use in combination with replaceable ampoules or carpules, e.g. automatic
- A61M2005/2403—Ampoule inserted into the ampoule holder
- A61M2005/2407—Ampoule inserted into the ampoule holder from the rear
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/24—Ampoule syringes, i.e. syringes with needle for use in combination with replaceable ampoules or carpules, e.g. automatic
- A61M2005/2485—Ampoule holder connected to rest of syringe
- A61M2005/2496—Ampoule holder connected to rest of syringe via pivot
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M2005/3125—Details specific display means, e.g. to indicate dose setting
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
- A61M5/31511—Piston or piston-rod constructions, e.g. connection of piston with piston-rod
- A61M2005/31518—Piston or piston-rod constructions, e.g. connection of piston with piston-rod designed to reduce the overall size of an injection device, e.g. using flexible or pivotally connected chain-like rod members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
- A61M5/31565—Administration mechanisms, i.e. constructional features, modes of administering a dose
- A61M5/31576—Constructional features or modes of drive mechanisms for piston rods
- A61M2005/31588—Constructional features or modes of drive mechanisms for piston rods electrically driven
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/27—General characteristics of the apparatus preventing use
- A61M2205/273—General characteristics of the apparatus preventing use preventing reuse, e.g. of disposables
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/33—Controlling, regulating or measuring
- A61M2205/3368—Temperature
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/36—General characteristics of the apparatus related to heating or cooling
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/36—General characteristics of the apparatus related to heating or cooling
- A61M2205/3606—General characteristics of the apparatus related to heating or cooling cooled
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/50—General characteristics of the apparatus with microprocessors or computers
- A61M2205/52—General characteristics of the apparatus with microprocessors or computers with memories providing a history of measured variating parameters of apparatus or patient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/58—Means for facilitating use, e.g. by people with impaired vision
- A61M2205/581—Means for facilitating use, e.g. by people with impaired vision by audible feedback
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/58—Means for facilitating use, e.g. by people with impaired vision
- A61M2205/582—Means for facilitating use, e.g. by people with impaired vision by tactile feedback
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/58—Means for facilitating use, e.g. by people with impaired vision
- A61M2205/583—Means for facilitating use, e.g. by people with impaired vision by visual feedback
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/60—General characteristics of the apparatus with identification means
- A61M2205/6054—Magnetic identification systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/32—Needles; Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
- A61M5/3205—Apparatus for removing or disposing of used needles or syringes, e.g. containers; Means for protection against accidental injuries from used needles
- A61M5/321—Means for protection against accidental injuries by used needles
- A61M5/3243—Means for protection against accidental injuries by used needles being axially-extensible, e.g. protective sleeves coaxially slidable on the syringe barrel
- A61M5/326—Fully automatic sleeve extension, i.e. in which triggering of the sleeve does not require a deliberate action by the user
-
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F04—POSITIVE - DISPLACEMENT MACHINES FOR LIQUIDS; PUMPS FOR LIQUIDS OR ELASTIC FLUIDS
- F04C—ROTARY-PISTON, OR OSCILLATING-PISTON, POSITIVE-DISPLACEMENT MACHINES FOR LIQUIDS; ROTARY-PISTON, OR OSCILLATING-PISTON, POSITIVE-DISPLACEMENT PUMPS
- F04C2270/00—Control; Monitoring or safety arrangements
- F04C2270/04—Force
- F04C2270/042—Force radial
- F04C2270/0421—Controlled or regulated
Definitions
- the invention relates to an autoinjector for administering a medicament.
- Administering an injection is a process which presents a number of risks and challenges for users and healthcare professionals, both mental and physical.
- Injection devices typically fall into two categories—manual devices and autoinjectors.
- manual force is required to drive a medicament through a needle. This is typically done by some form of button/plunger that has to be continuously pressed during the injection.
- button/plunger that has to be continuously pressed during the injection.
- There are numerous disadvantages associated with this approach For example, if the button/plunger is released prematurely, the injection will stop and may not deliver an intended dose. Further, the force required to push the button/plunger may be too high (e.g., if the user is elderly or a child). And, aligning the injection device, administering the injection and keeping the injection device still during the injection may require dexterity which some patients (e.g., elderly patients, children, arthritic patients, etc.) may not have.
- Autoinjector devices aim to make self-injection easier for patients.
- a conventional autoinjector may provide the force for administering the injection by a spring, and trigger button or other mechanism may be used to activate the injection.
- Autoinjectors may be single-use or reusable devices.
- Autoinjectors may be mechanical, electro-mechanical or fully electronic.
- Conventional mechanical autoinjectors may automatically provide the required force for needle insertion and medicament delivery, but may not provide additional functionality (e.g., alignment verification, injection site verification, etc.) which may be capable with electro-mechanical and fully electronic autoinjectors.
- WO 2005/077441 A2 discloses a hand-held, electronically controlled injection device for injecting preset doses of liquid medications, having a housing for receiving a cartridge containing the liquid medication and having a contact surface for contacting a patient's skin; and actuator means for moving the cartridge within the housing to and from the contact surface.
- U.S. Pat. No. 3,712,301 A discloses a hypodermic injector comprising a sleeve housing a cocked spring impelled plunger, a cartridge holder with a cannula pierceable stopper at the front end thereof attached to the sleeve and a cartridge with front end attached cannula in the holder wherein the rear end only of the cartridge is frictionally retained in the holder and in air tight sealing engagement therewith, the cartridge being otherwise substantially unrestrained from movement with respect to the holder, the free end of the cannula lying within the holder until the plunger is released, all to maintain cannula sterility and yet allow rapid movement of the cartridge in the holder when the plunger is operative.
- U.S. Pat. No. 3,742,948 A discloses a hypodermic syringe comprising a liquid container and a needle connected thereto at one end, which assembly is incorporated in a housing, the liquid container being bounded at the other end by a piston, and an operating mechanism being present to exert a force on the piston, one or more blocking elements being present for locking the operating mechanism or the piston against movement relative to the liquid container, the housing showing a diameter transition such that when the blocking elements pass along it, they are moved radially so that the blocking is removed and the piston penetrates into the liquid container so that the liquid flows out through the needle.
- EP 2 468 340 A1 discloses an auto-injector for administering a dose of a liquid medicament, comprising: —a substantially tubular front-end device adapted to contain a syringe with an injection needle and a barrel containing the dose of the medicament and comprising a needle shroud adapted to rest on the skin of a patient receiving an injection and—a reusable backend device comprising—a housing, a plunger connected to or adapted to engage a stopper providing a fluid tight seal for a distal end of the barrel, —a motor for displacing the plunger connected to the stopper, wherein the front-end device is attachable to the backend device, wherein the needle shroud is slidably arranged with respect to the injection needle and wherein an interlock switch is capable of detecting an axial position of the needle shroud.
- an autoinjector comprises a case, a motor adapted to rotate a drive gear, and a curvi-linear plunger adapted to mate with the drive gear.
- the plunger includes a distal end with a resilient flange, which in a non-deflected state, abuts a proximal collar of a syringe, and, in a deflected state, advances through the proximal collar and engages a stopper in the syringe.
- an autoinjector according to the present invention further comprises a door adapted to cover an opening in the case when the door is in a closed position.
- an autoinjector according to the present invention further comprises a door spring biasing the door in an open position.
- an autoinjector according to the present invention further comprises a releasable door latch adapted to lock the door in the closed position.
- an autoinjector according to the present invention further comprises a gear train coupled to the motor.
- the gear train includes a linkage having a threaded end adapted to mate with the drive gear.
- the plunger may comprise a plurality of hinged links.
- an autoinjector according to the present invention further comprises a plurality of guides disposed within the case, and the plunger engages the guides.
- an autoinjector according to the present invention further comprises an energy source including a rechargeable or non-rechargeable battery.
- an autoinjector according to the present invention further comprises a retraction spring biasing the syringe in a retracted position within the case.
- an autoinjector further comprises a boot removal mechanism comprising a gear adapted to rotate when the door transitions from an open position to the closed position, a rack adapted to mate with the gear and axially translate when the gear rotates, resilient locking beams adapted to grip a needle boot disposed on a needle of the syringe, and a boot removal spring applying a biasing force to the rack.
- the boot removal spring is compressed when the door transitions from the open position to the closed position.
- an autoinjector according to the present invention further comprises a user interface adapted to provide at least one of visual and audible feedback and instruction.
- an autoinjector further comprises a sensor arrangement adapted to detect proximity and properties of an injection site surface.
- the sensor arrangement comprises at least one near infrared light emitting diode (LED) adapted to illuminate the injection site surface, and a camera adapted to obtain an image of the injection site surface.
- the sensor arrangement comprises a projector adapted to display a pattern on the injection site surface.
- drug or “medicament”, as used herein, means a pharmaceutical formulation containing at least one pharmaceutically active compound
- the pharmaceutically active compound has a molecular weight up to 1500 Da and/or is a peptide, a proteine, a polysaccharide, a vaccine, a DNA, a RNA, an enzyme, an antibody or a fragment thereof, a hormone or an oligonucleotide, or a mixture of the above-mentioned pharmaceutically active compound,
- the pharmaceutically active compound is useful for the treatment and/or prophylaxis of diabetes mellitus or complications associated with diabetes mellitus such as diabetic retinopathy, thromboembolism disorders such as deep vein or pulmonary thromboembolism, acute coronary syndrome (ACS), angina, myocardial infarction, cancer, macular degeneration, inflammation, hay fever, atherosclerosis and/or rheumatoid arthritis,
- diabetes mellitus or complications associated with diabetes mellitus such as diabetic retinopathy, thromboembolism disorders such as deep vein or pulmonary thromboembolism, acute coronary syndrome (ACS), angina, myocardial infarction, cancer, macular degeneration, inflammation, hay fever, atherosclerosis and/or rheumatoid arthritis,
- diabetes mellitus or complications associated with diabetes mellitus such as diabetic retinopathy, thromboembolism disorders such as deep vein or pulmonary thromboembolism, acute coronary
- the pharmaceutically active compound comprises at least one peptide for the treatment and/or prophylaxis of diabetes mellitus or complications associated with diabetes mellitus such as diabetic retinopathy,
- the pharmaceutically active compound comprises at least one human insulin or a human insulin analogue or derivative, glucagon-like peptide (GLP-1) or an analogue or derivative thereof, or exendin-3 or exendin-4 or an analogue or derivative of exendin-3 or exendin-4.
- GLP-1 glucagon-like peptide
- exendin-3 or exendin-4 or an analogue or derivative of exendin-3 or exendin-4.
- Insulin analogues are for example Gly(A21), Arg(B31), Arg(B32) human insulin; Lys(B3), Glu(B29) human insulin; Lys(B28), Pro(B29) human insulin; Asp(B28) human insulin; human insulin, wherein proline in position B28 is replaced by Asp, Lys, Leu, Val or Ala and wherein in position B29 Lys may be replaced by Pro; Ala(B26) human insulin; Des(B28-B30) human insulin; Des(B27) human insulin and Des(B30) human insulin.
- Insulin derivates are for example B29-N-myristoyl-des(B30) human insulin; B29-N-palmitoyl-des(B30) human insulin; B29-N-myristoyl human insulin; B29-N-palmitoyl human insulin; B28-N-myristoyl LysB28ProB29 human insulin; B28-N-palmitoyl-LysB28ProB29 human insulin; B30-N-myristoyl-ThrB29LysB30 human insulin; B30-N-palmitoyl-ThrB29LysB30 human insulin; B29-N—(N-palmitoyl-Y-glutamyl)-des(B30) human insulin; B29-N—(N-lithocholyl-Y-glutamyl)-des(B30) human insulin; B29-N-( ⁇ -carboxyheptadecanoyl)-des(B30) human insulin and B29-N-( ⁇ -carboxy
- Exendin-4 for example means Exendin-4(1-39), a peptide of the sequence H-His-Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2.
- Exendin-4 derivatives are for example selected from the following list of compounds:
- Hormones are for example hypophysis hormones or hypothalamus hormones or regulatory active peptides and their antagonists as listed in Rote Liste, ed. 2008, Chapter 50, such as Gonadotropine (Follitropin, Lutropin, Choriongonadotropin, Menotropin), Somatropine (Somatropin), Desmopressin, Terlipressin, Gonadorelin, Triptorelin, Leuprorelin, Buserelin, Nafarelin, Goserelin.
- Gonadotropine Follitropin, Lutropin, Choriongonadotropin, Menotropin
- Somatropine Somatropin
- Desmopressin Terlipressin
- Gonadorelin Triptorelin
- Leuprorelin Buserelin
- Nafarelin Goserelin.
- a polysaccharide is for example a glucosaminoglycane, a hyaluronic acid, a heparin, a low molecular weight heparin or an ultra low molecular weight heparin or a derivative thereof, or a sulphated, e.g. a poly-sulphated form of the above-mentioned polysaccharides, and/or a pharmaceutically acceptable salt thereof.
- An example of a pharmaceutically acceptable salt of a poly-sulphated low molecular weight heparin is enoxaparin sodium.
- Antibodies are globular plasma proteins ( ⁇ 150 kDa) that are also known as immunoglobulins which share a basic structure. As they have sugar chains added to amino acid residues, they are glycoproteins.
- the basic functional unit of each antibody is an immunoglobulin (Ig) monomer (containing only one Ig unit); secreted antibodies can also be dimeric with two Ig units as with IgA, tetrameric with four Ig units like teleost fish IgM, or pentameric with five Ig units, like mammalian IgM.
- Ig immunoglobulin
- the Ig monomer is a “Y”-shaped molecule that consists of four polypeptide chains; two identical heavy chains and two identical light chains connected by disulfide bonds between cysteine residues. Each heavy chain is about 440 amino acids long; each light chain is about 220 amino acids long. Heavy and light chains each contain intrachain disulfide bonds which stabilize their folding. Each chain is composed of structural domains called Ig domains. These domains contain about 70-110 amino acids and are classified into different categories (for example, variable or V, and constant or C) according to their size and function. They have a characteristic immunoglobulin fold in which two sheets create a “sandwich” shape, held together by interactions between conserved cysteines and other charged amino acids.
- Ig heavy chain There are five types of mammalian Ig heavy chain denoted by ⁇ , ⁇ , ⁇ , ⁇ , and ⁇ .
- the type of heavy chain present defines the isotype of antibody; these chains are found in IgA, IgD, IgE, IgG, and IgM antibodies, respectively.
- Distinct heavy chains differ in size and composition; ⁇ and ⁇ contain approximately 450 amino acids and ⁇ approximately 500 amino acids, while ⁇ and ⁇ have approximately 550 amino acids.
- Each heavy chain has two regions, the constant region (C H ) and the variable region (V H ).
- the constant region is essentially identical in all antibodies of the same isotype, but differs in antibodies of different isotypes.
- Heavy chains ⁇ , ⁇ and ⁇ have a constant region composed of three tandem Ig domains, and a hinge region for added flexibility; heavy chains ⁇ and ⁇ have a constant region composed of four immunoglobulin domains.
- the variable region of the heavy chain differs in antibodies produced by different B cells, but is the same for all antibodies produced by a single B cell or B cell clone.
- the variable region of each heavy chain is approximately 110 amino acids long and is composed of a single Ig domain.
- a light chain has two successive domains: one constant domain (CL) and one variable domain (VL).
- CL constant domain
- VL variable domain
- the approximate length of a light chain is 211 to 217 amino acids.
- Each antibody contains two light chains that are always identical; only one type of light chain, ⁇ or ⁇ , is present per antibody in mammals.
- variable (V) regions are responsible for binding to the antigen, i.e. for its antigen specificity.
- VL variable light
- VH variable heavy chain
- CDRs Complementarity Determining Regions
- an “antibody fragment” contains at least one antigen binding fragment as defined above, and exhibits essentially the same function and specificity as the complete antibody of which the fragment is derived from.
- Limited proteolytic digestion with papain cleaves the Ig prototype into three fragments. Two identical amino terminal fragments, each containing one entire L chain and about half an H chain, are the antigen binding fragments (Fab).
- the Fc contains carbohydrates, complement-binding, and FcR-binding sites.
- F(ab′)2 is divalent for antigen binding.
- the disulfide bond of F(ab′)2 may be cleaved in order to obtain Fab′.
- the variable regions of the heavy and light chains can be fused together to form a single chain variable fragment (scFv).
- Pharmaceutically acceptable salts are for example acid addition salts and basic salts.
- Acid addition salts are e.g. HCl or HBr salts.
- Basic salts are e.g. salts having a cation selected from alkali or alkaline, e.g. Na+, or K+, or Ca2+, or an ammonium ion N+(R1)(R2)(R3)(R4), wherein R1 to R4 independently of each other mean: hydrogen, an optionally substituted C1-C6-alkyl group, an optionally substituted C2-C6-alkenyl group, an optionally substituted C6-C10-aryl group, or an optionally substituted C6-C10-heteroaryl group.
- solvates are for example hydrates.
- FIG. 1 is a front view of an exemplary embodiment of an autoinjector
- FIG. 2 is a side view of an exemplary embodiment of an autoinjector
- FIG. 3 is a rear view of an exemplary embodiment of an autoinjector
- FIG. 4 is a perspective view of an exemplary embodiment of a syringe for use with an autoinjector according to the present invention
- FIG. 5 is a perspective view of an exemplary embodiment of a syringe for use with an autoinjector according to the present invention
- FIG. 6 is a perspective view of an exemplary embodiment of a syringe for use with an autoinjector according to the present invention
- FIG. 7 is a perspective detail view an exemplary embodiment of a needle boot removal mechanism according to the present invention.
- FIG. 8 is a perspective detail view an exemplary embodiment of a needle boot removal mechanism according to the present invention.
- FIG. 9 is a longitudinal section of an exemplary embodiment of a plunger in an autoinjector according to the present invention.
- FIG. 10 is a longitudinal section of an exemplary embodiment of an autoinjector prior to needle extension according to the present invention.
- FIG. 11 is a longitudinal section of an exemplary embodiment of an autoinjector with the extended needle and a stopper advanced for emptying the syringe according to the present invention
- FIG. 12 is a perspective semitransparent detail view of an exemplary embodiment of an autoinjector with the needle a sensor arrangement
- FIG. 13 is an exemplary embodiment of an illumination of a flat surface by an exemplary embodiment of a sensor arrangement according to the present invention.
- FIG. 14 is an exemplary embodiment of an illumination of a contoured surface by an exemplary embodiment of a sensor arrangement according to the present invention.
- FIGS. 1-3 show front, side and rear views, respectively, of an exemplary embodiment of an autoinjector 1 according to the present invention.
- the autoinjector 1 comprises a case 2 with a contact surface 3 intended to be applied against the skin of a patient.
- the case 2 may have a generally elongate, rectangular shape and may include one or more ergonomic features (e.g., finger grooves for gripping) and/or textured surfaces or skins for preventing a user's hand from slipping while using the autoinjector 1 .
- the case 2 includes a door 22 which is configurable in an open position or a closed position.
- the door 22 provides access to a syringe carrier in the case 2 that is adapted to hold a syringe or a cartridge containing a medicament.
- the door 22 may be locked.
- the door 22 may be formed on a lateral side of the case 2 and rotate about a hinge between the open and closed positions.
- the syringe may be disposed in a channel formed in the case 2 , and the syringe carrier may not be utilized.
- a door spring 24 may be arranged in the case 2 to bias the door 22 to the open position.
- a door latch 25 may be formed on the case 2 and/or the door 22 to maintain the door 22 in the closed position.
- the door latch 25 may be rotated or deflected by a solenoid (not shown) to engage/disengage the case 2 and/or the door 22 to allow the door 22 to open and close.
- a used syringe may be removed from the syringe carrier and a new syringe may be inserted into the syringe carrier.
- a door stop 34 may be disposed in the case 2 for preventing the door 22 from rotating beyond the closed position.
- FIGS. 4-6 show an exemplary embodiment of a syringe 4 for use with the autoinjector 1 according to the present invention.
- the syringe 4 includes a body 5 containing a medicament and a case 6 coupled to the body 5 .
- the case 6 may include an attachment (e.g., hooks, snaps, etc.) which engage a finger flange 5 . 1 on a proximal end of the body 5 .
- a needle shield 9 is telescopically coupled to the case 6 and is biased relative to the case 6 by a spring 10 .
- a needle 7 is disposed at a distal end of the body 5 .
- a needle boot 8 is, as shown in FIG. 4 , arranged on the needle 7 , prior to use.
- FIG. 5 shows the syringe 4 with the needle boot 8 removed and the needle shield 9 in a retracted position, with the needle 7 exposed.
- FIG. 6 shows the syringe 4 with the needle shield 9 in an extended position, covering a distal tip of the needle 7 .
- the needle shield 9 may lock in the extended position to prevent reuse of the needle 7 .
- a data storage device 11 may be disposed on the syringe 4 and include data, such as a type and volume of the medicament, filling and/or expiration date of the medicament, temperature of the medicament (e.g., if there is a temperature sensor on or near the syringe 4 ), a manufacturer of the medicament and/or the autoinjector 1 , patient data (e.g., name, physician, dosing regiment, etc.), a used/unused indicator, etc.
- data such as a type and volume of the medicament, filling and/or expiration date of the medicament, temperature of the medicament (e.g., if there is a temperature sensor on or near the syringe 4 ), a manufacturer of the medicament and/or the autoinjector 1 , patient data (e.g., name, physician, dosing regiment, etc.), a used/unused indicator, etc.
- the autoinjector 1 includes a motor 15 adapted to drive a plunger rod 18 .
- the motor 15 may be coupled to a gear train 17 , which may comprise a gearbox 17 . 1 and a linkage 17 . 2 .
- the gear train 17 may reduce an output speed of the motor 15 to increase its torque.
- the linkage 17 . 2 includes a threaded end, such as a worm gear 21 .
- the worm gear 21 mates with a drive gear 20 .
- the drive gear 20 includes teeth 18 . 3 which mate with notches formed in links 18 . 2 of the plunger 18 .
- Consecutive links 18 . 2 of the plunger 18 are hingedly attached, allowing the plunger 18 to vary between a rotated state (wrapped around the drive gear 20 ) and an axial state (unwrapped from the drive gear 20 ).
- the links 18 . 2 may contain a resilient element which biases consecutive links 18 . 2 in the axial state.
- the curvi-linear plunger 18 may reduce a form factor of the autoinjector 1 .
- the plunger 18 could be driven by, for example, a lead screw or rack and pinion geared transmission from the motor 15 .
- the plunger 18 may be arranged as a telescopic plunger or as a curved spring or tape or as a helical spring, flexible rack or segmented piston. Rollers or guide elements (shown in FIG. 9 ) may be disposed within the autoinjector 1 to ensure a proper path of travel of the plunger 18 as it rotates and extends.
- the autoinjector 1 includes an energy source 12 , which may comprise one or more batteries, rechargeable or non-rechargeable. Rechargeable batteries may be recharged by connecting the autoinjector 1 to an external power supply, e.g. by plugging-in a power cable, by locating the autoinjector 1 in a docking station or by wireless inductive charging.
- the energy source 12 is a rechargeable Lithium-Ion or Lithium-Polymer battery having a flat shape.
- FIG. 9 shows an exemplary embodiment of a distal end of the plunger 18 .
- the distal end of the plunger 18 may include resilient flanges 18 . 1 disposed on a radial surface of the plunger 18 .
- the resilient flanges 18 . 1 may include ramped or rounded edges which are adapted to engage a circumferential collar 5 . 2 disposed on a proximal opening of the syringe body 5 .
- a first diameter of the resilient flanges 18 . 1 is larger than a second diameter of a proximal opening of the syringe body 5 .
- the flanges 18 . 1 abut the collar 5 . 2 and push the syringe carrier (and the syringe 4 therein) distally relative to the case 2 until the syringe carrier is stopped (e.g., against the case 2 or a distal stop positioned in the case 2 ) which results in insertion of the needle 7 through aperture 3 . 1 into the injection site.
- the flanges 18 . 1 transition to a deflected state, allowing the plunger 18 to enter the syringe body 5 and push the stopper 19 to dispense the medicament.
- a retraction spring 28 biases the syringe carrier in a retracted position in the case 2 .
- the retraction spring 28 is compressed.
- the retraction spring bears on the syringe carrier.
- the retraction spring 28 may bear on a rib 6 . 1 formed on the syringe case 6 .
- the autoinjector 1 may not utilize a syringe carrier, but include a channel adapted to receive the syringe 4 .
- a proximal stop may be positioned in the case 2 to prevent the syringe carrier from moving proximally beyond the retracted position.
- the autoinjector 1 includes a data processing unit 13 which controls operation of the autoinjector 1 .
- the data processing unit 13 may include a microprocessor and memory. As described further herein, the data processing unit 13 may process/store data and control operation of the autoinjector 1 . For example, the data processing unit 13 may read data from and/or write data to the data storage device 11 on the syringe 4 .
- At least one encoder is utilized to provide a data signal to the data processing unit 13 which is used to determine a position of the plunger 18 .
- the encoder may be optical, mechanical, magnetic, etc. to detect a position of the plunger 18 .
- the encoder may be disposed on the drive gear 20 to sense angular rotation, and the data processing unit 13 may determine a position of the plunger 18 may on the rotation data.
- an exemplary embodiment of the autoinjector 1 may include a boot removal mechanism 29 for removing the needle boot 8 from the needle 7 .
- the boot removal mechanism 29 comprises a gear 30 which mates with a rack 31 disposed in the case 2 .
- the gear 30 is rotated by the closing of the door 22 .
- the gear 30 rotates, causing the rack 31 to advance in the proximal direction and compressing a boot removal spring 26 .
- Resilient locking beams 32 coupled to the rack 31 are advanced over the needle boot 8 until hooks on the locking beam 32 engage a proximal end of the needle boot 8 .
- the locking beams 32 may be retained in this position by a solenoid.
- the solenoid Prior to an injection, the solenoid is discharged to release the locking beams 32 , which under the biasing force of the boot removal spring 26 , push the needle boot 8 off of the needle 7 and at least partially through the aperture 3 . 1 (so the user can manually remove the needle boot 8 completely).
- the boot removal mechanism 29 may be configured for completely removing the needle boot 8 from the needle 7 (e.g., by using a more powerful boot removal spring 26 ).
- the autoinjector 1 comprises a user interface which may include visual and acoustic components, such as LEDs, a display, a touch screen 14 , a speaker, a microphone, buttons, dials, switches, etc.
- the data processing unit 13 may, for example, provide visual/audible cues to guide the user through an injection process, alert that a patient is due for an injection, provide distraction and/or re-assurance during the injection, providing data about the medicament (e.g., obtained from the data storage device 11 ), etc.
- the user interface may, for example, be used to configure a patient profile, configure insertion depth, injection speed, and medicament type, provide user feedback of comfort in injection, display instructions on loading or reloading of a syringe 4 , authenticate a user, provide visual/audio/vibration feedback to the user to indicate injection progress, injection completion, historical user data, drug properties (e.g. use by date), etc.
- the user interface includes a trigger button 16 disposed on the case 2 for activating the injection process.
- a heater/cooling device (not illustrated) may be arranged within the case 2 for heating or cooling the medicament.
- FIG. 12 shows an exemplary embodiment of a sensor arrangement 27 for use with the autoinjector 1 according to the present invention.
- the sensor arrangement 27 is arranged in or behind the contact surface 3 for detecting veins, scar tissue, detecting contact with the injection site, and/or detecting an angle of the needle 7 with respect to the injection site.
- the sensor arrangement 27 comprises at least one near infrared LED 27 . 1 , a projector 27 . 2 and a camera 27 . 3 .
- the near infrared LEDs 27 . 1 are arranged to illuminate the injection site, and the camera 27 . 3 may then obtain an image of the injection site to determine whether veins or scars are present, which would indicate an undesirable injection site.
- the camera 27 .
- the projector 27 . 2 may comprise a laser and a diffractive optical element arranged to project a planar grid 33 onto the injection site which may be detected by the camera 27 . 3 .
- Orientation of the autoinjector 1 relative to the injection site and/or injection site abnormalities may be determined from a distortion of the grid 33 detected by the camera 27 . 3 .
- FIGS. 13 and 14 show exemplary embodiments of the grid 33 indicating a relatively flat injection site surface ( FIG. 13 ) and contoured injection site surface ( FIG. 14 ), the latter of which may be undesirable for an injection.
- An exemplary sequence of operation for the autoinjector 1 may be as follows:
- the autoinjector 1 may provide an injection alert (e.g., based on a treatment protocol schedule) indicating it is time to administer an injection.
- the user interface may provide various details about the injection, e.g., day/time of last injection, medicament to inject, day/time for a subsequent injection, etc.
- the autoinjector 1 may remain in a low-power or “sleep” mode until it provides the injection alert or is manually activated by a user.
- the door 22 When the autoinjector 1 is activated, the door 22 is opened and a syringe 4 is placed in the syringe carrier. As the door 22 is closed, the boot removal mechanism 29 is operated to engage the needle boot 8 on the syringe 4 . After the door 22 is closed, the door latch 25 may lock the door 22 in the closed position.
- the data processing unit 13 may perform various functions such as, for example, authenticating the syringe 4 (via data on the data storage device 11 ), detecting medicament conditions (e.g., temperature, expiry date, etc.), and initializing mechanical, electronic and optical components of the autoinjector 1 to ensure that all are in working conditions.
- authenticating the syringe 4 via data on the data storage device 11
- detecting medicament conditions e.g., temperature, expiry date, etc.
- initializing mechanical, electronic and optical components of the autoinjector 1 to ensure that all are in working conditions.
- the heater/cooling device may heat/cool the medicament as appropriate.
- the user interface may notify the user when the autoinjector 1 is ready for the injection. If, for example, the user presses the trigger button 16 a first time, the solenoid of the boot removal mechanism 29 may be discharged, and the needle boot 8 may be at least partially disengaged from the needle 7 and presented through the aperture 3 . 1 . The user may then remove the needle boot 8 , while maintaining needle safety, because the needle 7 remains fully enclosed by the case 2 .
- the sensor arrangement 27 may provide various information to the data processing unit 13 to determine if the injection site is adequate (e.g., aligned properly, no veins/scars detected, relatively flat surface, etc.).
- the autoinjector 1 is ready for the injection.
- the motor 15 rotates the drive gear 20 to rotate and advance the plunger 18 .
- the resilient flange 18 . 1 of the plunger engages the proximal collar 5 . 2 of the syringe body 5 and pushes the syringe 4 (and/or the syringe carrier) in the distal direction, compressing the retraction spring 28 .
- the syringe carrier abuts a distal stop in the case 2 , the needle 7 is extended through the aperture 3 . 1 and inserted into the injection site.
- the continued rotation of the drive gear 20 causes the resilient flange 18 . 1 to deflect, allowing the plunger 18 to enter the syringe body 5 and engage the stopper 19 .
- the plunger 18 pushes the stopper 19 distally within the syringe body 5 to dispense the medicament through the needle 7 , as shown in FIG. 11 .
- the motor 15 may release tension on the drive gear 20 , allowing the force of the retraction spring 28 to push the syringe carrier in the proximal direction to withdraw the needle 7 from the injection site.
- the motor 15 may reverse and rotate the drive gear 20 in an opposite rotational direction to withdraw force on the syringe carrier.
- the drive gear 20 may disengage the motor 15 , releasing force on the syringe carrier.
- the needle shield 9 on the syringe 4 may be deployed under the force of the spring 10 .
- a latch on the needle shield 9 may be disengaged and allow the spring 10 to push the needle shield 9 .
- the needle shield 9 may abut the distal end of the case 2 .
- the retraction spring 28 may push the syringe 4 a sufficient distance in the proximal direction to ensure that the needle shield 9 can achieve the extended position.
- the door 22 may be opened and the used syringe 4 may be removed. Because the needle shield 9 is in the extended position, the needle 7 is fully covered, significantly reducing the risk of needle stick injuries.
- the autoinjector 1 may continuously monitor its status and provide feedback/instructions to the user via the user interface.
- the data processing unit 13 may monitor position of the plunger 13 , contact between the autoinjector 1 and the injection site, etc.
- the autoinjector 1 may be controlled to immediately stop dispensing the drug and retract the needle 7 . Controlling the needle insertion speed, dispense rate and needle insertion depth may improve patient comfort and compliance with a treatment protocol.
Landscapes
- Health & Medical Sciences (AREA)
- Vascular Medicine (AREA)
- Engineering & Computer Science (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dermatology (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
Abstract
Description
- The present application is a continuation of U.S. patent application Ser. No. 14/421,020, filed Feb. 11, 2015, which is a U.S. National Phase Application pursuant to 35 U.S.C. § 371 of International Application No. PCT/EP2013/066775 filed Aug. 12, 2013, which claims priority to European Patent Application No. 12180577.4 filed Aug. 15, 2012. The entire disclosure contents of these applications are herewith incorporated by reference into the present application.
- The invention relates to an autoinjector for administering a medicament.
- Administering an injection is a process which presents a number of risks and challenges for users and healthcare professionals, both mental and physical. Injection devices typically fall into two categories—manual devices and autoinjectors. In a conventional manual device, manual force is required to drive a medicament through a needle. This is typically done by some form of button/plunger that has to be continuously pressed during the injection. There are numerous disadvantages associated with this approach. For example, if the button/plunger is released prematurely, the injection will stop and may not deliver an intended dose. Further, the force required to push the button/plunger may be too high (e.g., if the user is elderly or a child). And, aligning the injection device, administering the injection and keeping the injection device still during the injection may require dexterity which some patients (e.g., elderly patients, children, arthritic patients, etc.) may not have.
- Autoinjector devices aim to make self-injection easier for patients. A conventional autoinjector may provide the force for administering the injection by a spring, and trigger button or other mechanism may be used to activate the injection. Autoinjectors may be single-use or reusable devices.
- Autoinjectors may be mechanical, electro-mechanical or fully electronic. Conventional mechanical autoinjectors may automatically provide the required force for needle insertion and medicament delivery, but may not provide additional functionality (e.g., alignment verification, injection site verification, etc.) which may be capable with electro-mechanical and fully electronic autoinjectors.
- WO 2005/077441 A2 discloses a hand-held, electronically controlled injection device for injecting preset doses of liquid medications, having a housing for receiving a cartridge containing the liquid medication and having a contact surface for contacting a patient's skin; and actuator means for moving the cartridge within the housing to and from the contact surface.
- U.S. Pat. No. 3,712,301 A discloses a hypodermic injector comprising a sleeve housing a cocked spring impelled plunger, a cartridge holder with a cannula pierceable stopper at the front end thereof attached to the sleeve and a cartridge with front end attached cannula in the holder wherein the rear end only of the cartridge is frictionally retained in the holder and in air tight sealing engagement therewith, the cartridge being otherwise substantially unrestrained from movement with respect to the holder, the free end of the cannula lying within the holder until the plunger is released, all to maintain cannula sterility and yet allow rapid movement of the cartridge in the holder when the plunger is operative.
- U.S. Pat. No. 3,742,948 A discloses a hypodermic syringe comprising a liquid container and a needle connected thereto at one end, which assembly is incorporated in a housing, the liquid container being bounded at the other end by a piston, and an operating mechanism being present to exert a force on the piston, one or more blocking elements being present for locking the operating mechanism or the piston against movement relative to the liquid container, the housing showing a diameter transition such that when the blocking elements pass along it, they are moved radially so that the blocking is removed and the piston penetrates into the liquid container so that the liquid flows out through the needle.
-
EP 2 468 340 A1 discloses an auto-injector for administering a dose of a liquid medicament, comprising: —a substantially tubular front-end device adapted to contain a syringe with an injection needle and a barrel containing the dose of the medicament and comprising a needle shroud adapted to rest on the skin of a patient receiving an injection and—a reusable backend device comprising—a housing, a plunger connected to or adapted to engage a stopper providing a fluid tight seal for a distal end of the barrel, —a motor for displacing the plunger connected to the stopper, wherein the front-end device is attachable to the backend device, wherein the needle shroud is slidably arranged with respect to the injection needle and wherein an interlock switch is capable of detecting an axial position of the needle shroud. - Thus, there remains a need for an improved autoinjector.
- It is an object of the present invention to provide an improved autoinjector.
- In an exemplary embodiment, an autoinjector according to the present invention comprises a case, a motor adapted to rotate a drive gear, and a curvi-linear plunger adapted to mate with the drive gear. The plunger includes a distal end with a resilient flange, which in a non-deflected state, abuts a proximal collar of a syringe, and, in a deflected state, advances through the proximal collar and engages a stopper in the syringe.
- In an exemplary embodiment, an autoinjector according to the present invention further comprises a door adapted to cover an opening in the case when the door is in a closed position. In an exemplary embodiment, an autoinjector according to the present invention further comprises a door spring biasing the door in an open position. In an exemplary embodiment, an autoinjector according to the present invention further comprises a releasable door latch adapted to lock the door in the closed position.
- In an exemplary embodiment, an autoinjector according to the present invention further comprises a gear train coupled to the motor. The gear train includes a linkage having a threaded end adapted to mate with the drive gear.
- The plunger may comprise a plurality of hinged links.
- In an exemplary embodiment, an autoinjector according to the present invention further comprises a plurality of guides disposed within the case, and the plunger engages the guides.
- In an exemplary embodiment, an autoinjector according to the present invention further comprises an energy source including a rechargeable or non-rechargeable battery.
- In an exemplary embodiment, an autoinjector according to the present invention further comprises a retraction spring biasing the syringe in a retracted position within the case.
- In an exemplary embodiment, an autoinjector according to the present invention further comprises a boot removal mechanism comprising a gear adapted to rotate when the door transitions from an open position to the closed position, a rack adapted to mate with the gear and axially translate when the gear rotates, resilient locking beams adapted to grip a needle boot disposed on a needle of the syringe, and a boot removal spring applying a biasing force to the rack. The boot removal spring is compressed when the door transitions from the open position to the closed position.
- In an exemplary embodiment, an autoinjector according to the present invention further comprises a user interface adapted to provide at least one of visual and audible feedback and instruction.
- In an exemplary embodiment, an autoinjector according to the present invention further comprises a sensor arrangement adapted to detect proximity and properties of an injection site surface. The sensor arrangement comprises at least one near infrared light emitting diode (LED) adapted to illuminate the injection site surface, and a camera adapted to obtain an image of the injection site surface. In another exemplary embodiment, the sensor arrangement comprises a projector adapted to display a pattern on the injection site surface.
- The term “drug” or “medicament”, as used herein, means a pharmaceutical formulation containing at least one pharmaceutically active compound,
- wherein in one embodiment the pharmaceutically active compound has a molecular weight up to 1500 Da and/or is a peptide, a proteine, a polysaccharide, a vaccine, a DNA, a RNA, an enzyme, an antibody or a fragment thereof, a hormone or an oligonucleotide, or a mixture of the above-mentioned pharmaceutically active compound,
- wherein in a further embodiment the pharmaceutically active compound is useful for the treatment and/or prophylaxis of diabetes mellitus or complications associated with diabetes mellitus such as diabetic retinopathy, thromboembolism disorders such as deep vein or pulmonary thromboembolism, acute coronary syndrome (ACS), angina, myocardial infarction, cancer, macular degeneration, inflammation, hay fever, atherosclerosis and/or rheumatoid arthritis,
- wherein in a further embodiment the pharmaceutically active compound comprises at least one peptide for the treatment and/or prophylaxis of diabetes mellitus or complications associated with diabetes mellitus such as diabetic retinopathy,
- wherein in a further embodiment the pharmaceutically active compound comprises at least one human insulin or a human insulin analogue or derivative, glucagon-like peptide (GLP-1) or an analogue or derivative thereof, or exendin-3 or exendin-4 or an analogue or derivative of exendin-3 or exendin-4.
- Insulin analogues are for example Gly(A21), Arg(B31), Arg(B32) human insulin; Lys(B3), Glu(B29) human insulin; Lys(B28), Pro(B29) human insulin; Asp(B28) human insulin; human insulin, wherein proline in position B28 is replaced by Asp, Lys, Leu, Val or Ala and wherein in position B29 Lys may be replaced by Pro; Ala(B26) human insulin; Des(B28-B30) human insulin; Des(B27) human insulin and Des(B30) human insulin.
- Insulin derivates are for example B29-N-myristoyl-des(B30) human insulin; B29-N-palmitoyl-des(B30) human insulin; B29-N-myristoyl human insulin; B29-N-palmitoyl human insulin; B28-N-myristoyl LysB28ProB29 human insulin; B28-N-palmitoyl-LysB28ProB29 human insulin; B30-N-myristoyl-ThrB29LysB30 human insulin; B30-N-palmitoyl-ThrB29LysB30 human insulin; B29-N—(N-palmitoyl-Y-glutamyl)-des(B30) human insulin; B29-N—(N-lithocholyl-Y-glutamyl)-des(B30) human insulin; B29-N-(ω-carboxyheptadecanoyl)-des(B30) human insulin and B29-N-(ω-carboxyheptadecanoyl) human insulin.
- Exendin-4 for example means Exendin-4(1-39), a peptide of the sequence H-His-Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2.
- Exendin-4 derivatives are for example selected from the following list of compounds:
- wherein the group -Lys6-NH2 may be bound to the C-terminus of the Exendin-4 derivative;
or an Exendin-4 derivative of the sequence - or a pharmaceutically acceptable salt or solvate of any one of the afore-mentioned Exendin-4 derivative.
- Hormones are for example hypophysis hormones or hypothalamus hormones or regulatory active peptides and their antagonists as listed in Rote Liste, ed. 2008, Chapter 50, such as Gonadotropine (Follitropin, Lutropin, Choriongonadotropin, Menotropin), Somatropine (Somatropin), Desmopressin, Terlipressin, Gonadorelin, Triptorelin, Leuprorelin, Buserelin, Nafarelin, Goserelin.
- A polysaccharide is for example a glucosaminoglycane, a hyaluronic acid, a heparin, a low molecular weight heparin or an ultra low molecular weight heparin or a derivative thereof, or a sulphated, e.g. a poly-sulphated form of the above-mentioned polysaccharides, and/or a pharmaceutically acceptable salt thereof. An example of a pharmaceutically acceptable salt of a poly-sulphated low molecular weight heparin is enoxaparin sodium.
- Antibodies are globular plasma proteins (˜150 kDa) that are also known as immunoglobulins which share a basic structure. As they have sugar chains added to amino acid residues, they are glycoproteins. The basic functional unit of each antibody is an immunoglobulin (Ig) monomer (containing only one Ig unit); secreted antibodies can also be dimeric with two Ig units as with IgA, tetrameric with four Ig units like teleost fish IgM, or pentameric with five Ig units, like mammalian IgM.
- The Ig monomer is a “Y”-shaped molecule that consists of four polypeptide chains; two identical heavy chains and two identical light chains connected by disulfide bonds between cysteine residues. Each heavy chain is about 440 amino acids long; each light chain is about 220 amino acids long. Heavy and light chains each contain intrachain disulfide bonds which stabilize their folding. Each chain is composed of structural domains called Ig domains. These domains contain about 70-110 amino acids and are classified into different categories (for example, variable or V, and constant or C) according to their size and function. They have a characteristic immunoglobulin fold in which two sheets create a “sandwich” shape, held together by interactions between conserved cysteines and other charged amino acids.
- There are five types of mammalian Ig heavy chain denoted by α, δ, ε, γ, and μ. The type of heavy chain present defines the isotype of antibody; these chains are found in IgA, IgD, IgE, IgG, and IgM antibodies, respectively.
- Distinct heavy chains differ in size and composition; α and γ contain approximately 450 amino acids and δ approximately 500 amino acids, while μ and ε have approximately 550 amino acids. Each heavy chain has two regions, the constant region (CH) and the variable region (VH). In one species, the constant region is essentially identical in all antibodies of the same isotype, but differs in antibodies of different isotypes. Heavy chains γ, α and δ have a constant region composed of three tandem Ig domains, and a hinge region for added flexibility; heavy chains μ and ε have a constant region composed of four immunoglobulin domains. The variable region of the heavy chain differs in antibodies produced by different B cells, but is the same for all antibodies produced by a single B cell or B cell clone. The variable region of each heavy chain is approximately 110 amino acids long and is composed of a single Ig domain.
- In mammals, there are two types of immunoglobulin light chain denoted by λ and κ. A light chain has two successive domains: one constant domain (CL) and one variable domain (VL). The approximate length of a light chain is 211 to 217 amino acids. Each antibody contains two light chains that are always identical; only one type of light chain, κ or λ, is present per antibody in mammals.
- Although the general structure of all antibodies is very similar, the unique property of a given antibody is determined by the variable (V) regions, as detailed above. More specifically, variable loops, three each the light (VL) and three on the heavy (VH) chain, are responsible for binding to the antigen, i.e. for its antigen specificity. These loops are referred to as the Complementarity Determining Regions (CDRs). Because CDRs from both VH and VL domains contribute to the antigen-binding site, it is the combination of the heavy and the light chains, and not either alone, that determines the final antigen specificity.
- An “antibody fragment” contains at least one antigen binding fragment as defined above, and exhibits essentially the same function and specificity as the complete antibody of which the fragment is derived from. Limited proteolytic digestion with papain cleaves the Ig prototype into three fragments. Two identical amino terminal fragments, each containing one entire L chain and about half an H chain, are the antigen binding fragments (Fab). The third fragment, similar in size but containing the carboxyl terminal half of both heavy chains with their interchain disulfide bond, is the crystalizable fragment (Fc). The Fc contains carbohydrates, complement-binding, and FcR-binding sites. Limited pepsin digestion yields a single F(ab′)2 fragment containing both Fab pieces and the hinge region, including the H—H interchain disulfide bond. F(ab′)2 is divalent for antigen binding. The disulfide bond of F(ab′)2 may be cleaved in order to obtain Fab′. Moreover, the variable regions of the heavy and light chains can be fused together to form a single chain variable fragment (scFv).
- Pharmaceutically acceptable salts are for example acid addition salts and basic salts. Acid addition salts are e.g. HCl or HBr salts. Basic salts are e.g. salts having a cation selected from alkali or alkaline, e.g. Na+, or K+, or Ca2+, or an ammonium ion N+(R1)(R2)(R3)(R4), wherein R1 to R4 independently of each other mean: hydrogen, an optionally substituted C1-C6-alkyl group, an optionally substituted C2-C6-alkenyl group, an optionally substituted C6-C10-aryl group, or an optionally substituted C6-C10-heteroaryl group. Further examples of pharmaceutically acceptable salts are described in “Remington's Pharmaceutical Sciences” 17. ed. Alfonso R. Gennaro (Ed.), Mark Publishing Company, Easton, Pa., U.S.A., 1985 and in Encyclopedia of Pharmaceutical Technology.
- Pharmaceutically acceptable solvates are for example hydrates.
- Further scope of applicability of the present invention will become apparent from the detailed description given hereinafter. However, it should be understood that the detailed description and specific examples, while indicating preferred embodiments of the invention, are given by way of illustration only, since various changes and modifications within the spirit and scope of the invention will become apparent to those skilled in the art from this detailed description.
- The present invention will become more fully understood from the detailed description given hereinbelow and the accompanying drawings which are given by way of illustration only, and thus, are not limitive of the present invention, and wherein:
-
FIG. 1 is a front view of an exemplary embodiment of an autoinjector, -
FIG. 2 is a side view of an exemplary embodiment of an autoinjector, -
FIG. 3 is a rear view of an exemplary embodiment of an autoinjector, -
FIG. 4 is a perspective view of an exemplary embodiment of a syringe for use with an autoinjector according to the present invention, -
FIG. 5 is a perspective view of an exemplary embodiment of a syringe for use with an autoinjector according to the present invention, -
FIG. 6 is a perspective view of an exemplary embodiment of a syringe for use with an autoinjector according to the present invention, -
FIG. 7 is a perspective detail view an exemplary embodiment of a needle boot removal mechanism according to the present invention, -
FIG. 8 is a perspective detail view an exemplary embodiment of a needle boot removal mechanism according to the present invention, -
FIG. 9 is a longitudinal section of an exemplary embodiment of a plunger in an autoinjector according to the present invention, -
FIG. 10 is a longitudinal section of an exemplary embodiment of an autoinjector prior to needle extension according to the present invention, -
FIG. 11 is a longitudinal section of an exemplary embodiment of an autoinjector with the extended needle and a stopper advanced for emptying the syringe according to the present invention, -
FIG. 12 is a perspective semitransparent detail view of an exemplary embodiment of an autoinjector with the needle a sensor arrangement, -
FIG. 13 is an exemplary embodiment of an illumination of a flat surface by an exemplary embodiment of a sensor arrangement according to the present invention, and -
FIG. 14 is an exemplary embodiment of an illumination of a contoured surface by an exemplary embodiment of a sensor arrangement according to the present invention. - Corresponding parts are marked with the same reference symbols in all figures.
-
FIGS. 1-3 show front, side and rear views, respectively, of an exemplary embodiment of anautoinjector 1 according to the present invention. - In an exemplary embodiment, the
autoinjector 1 comprises acase 2 with acontact surface 3 intended to be applied against the skin of a patient. Thecase 2 may have a generally elongate, rectangular shape and may include one or more ergonomic features (e.g., finger grooves for gripping) and/or textured surfaces or skins for preventing a user's hand from slipping while using theautoinjector 1. - In an exemplary embodiment, the
case 2 includes adoor 22 which is configurable in an open position or a closed position. In the open position, thedoor 22 provides access to a syringe carrier in thecase 2 that is adapted to hold a syringe or a cartridge containing a medicament. In the closed position, thedoor 22 may be locked. As shown in the exemplary embodiment inFIG. 1 , thedoor 22 may be formed on a lateral side of thecase 2 and rotate about a hinge between the open and closed positions. However, those of skill in the art will understand that thedoor 22 may be formed on any side or face of thecase 2 and may rotate, slide or translate relative to thecase 2 to open and close. In another exemplary embodiment, the syringe may be disposed in a channel formed in thecase 2, and the syringe carrier may not be utilized. - In an exemplary embodiment, a
door spring 24 may be arranged in thecase 2 to bias thedoor 22 to the open position. Adoor latch 25 may be formed on thecase 2 and/or thedoor 22 to maintain thedoor 22 in the closed position. In an exemplary embodiment, thedoor latch 25 may be rotated or deflected by a solenoid (not shown) to engage/disengage thecase 2 and/or thedoor 22 to allow thedoor 22 to open and close. When thedoor 22 is in the open position, a used syringe may be removed from the syringe carrier and a new syringe may be inserted into the syringe carrier. Adoor stop 34 may be disposed in thecase 2 for preventing thedoor 22 from rotating beyond the closed position. -
FIGS. 4-6 show an exemplary embodiment of asyringe 4 for use with theautoinjector 1 according to the present invention. Thesyringe 4 includes abody 5 containing a medicament and acase 6 coupled to thebody 5. Thecase 6 may include an attachment (e.g., hooks, snaps, etc.) which engage a finger flange 5.1 on a proximal end of thebody 5. Aneedle shield 9 is telescopically coupled to thecase 6 and is biased relative to thecase 6 by aspring 10. Aneedle 7 is disposed at a distal end of thebody 5. Aneedle boot 8 is, as shown inFIG. 4 , arranged on theneedle 7, prior to use.FIG. 5 shows thesyringe 4 with theneedle boot 8 removed and theneedle shield 9 in a retracted position, with theneedle 7 exposed.FIG. 6 shows thesyringe 4 with theneedle shield 9 in an extended position, covering a distal tip of theneedle 7. Theneedle shield 9 may lock in the extended position to prevent reuse of theneedle 7. - In an exemplary embodiment, a
data storage device 11 may be disposed on thesyringe 4 and include data, such as a type and volume of the medicament, filling and/or expiration date of the medicament, temperature of the medicament (e.g., if there is a temperature sensor on or near the syringe 4), a manufacturer of the medicament and/or theautoinjector 1, patient data (e.g., name, physician, dosing regiment, etc.), a used/unused indicator, etc. - Referring back to
FIG. 3 , theautoinjector 1 includes amotor 15 adapted to drive aplunger rod 18. In an exemplary embodiment, themotor 15 may be coupled to a gear train 17, which may comprise a gearbox 17.1 and a linkage 17.2. As understood by those of skill in the art, the gear train 17 may reduce an output speed of themotor 15 to increase its torque. - In an exemplary embodiment, the linkage 17.2 includes a threaded end, such as a worm gear 21. The worm gear 21 mates with a
drive gear 20. Thedrive gear 20 includes teeth 18.3 which mate with notches formed in links 18.2 of theplunger 18. Thus, when themotor 15 is actuated, the linkage 17.2 rotates the worm gear 21, which rotates thedrive gear 20, which advances or retracts theplunger 18. Consecutive links 18.2 of theplunger 18 are hingedly attached, allowing theplunger 18 to vary between a rotated state (wrapped around the drive gear 20) and an axial state (unwrapped from the drive gear 20). In an exemplary embodiment, the links 18.2 may contain a resilient element which biases consecutive links 18.2 in the axial state. As understood by those of skill in the art, the curvi-linear plunger 18 may reduce a form factor of theautoinjector 1. - In other exemplary embodiments, the
plunger 18 could be driven by, for example, a lead screw or rack and pinion geared transmission from themotor 15. In other exemplary embodiments, theplunger 18 may be arranged as a telescopic plunger or as a curved spring or tape or as a helical spring, flexible rack or segmented piston. Rollers or guide elements (shown inFIG. 9 ) may be disposed within theautoinjector 1 to ensure a proper path of travel of theplunger 18 as it rotates and extends. - In an exemplary embodiment, the
autoinjector 1 includes anenergy source 12, which may comprise one or more batteries, rechargeable or non-rechargeable. Rechargeable batteries may be recharged by connecting theautoinjector 1 to an external power supply, e.g. by plugging-in a power cable, by locating theautoinjector 1 in a docking station or by wireless inductive charging. In an exemplary embodiment, theenergy source 12 is a rechargeable Lithium-Ion or Lithium-Polymer battery having a flat shape. -
FIG. 9 shows an exemplary embodiment of a distal end of theplunger 18. The distal end of theplunger 18 may include resilient flanges 18.1 disposed on a radial surface of theplunger 18. In an exemplary embodiment, the resilient flanges 18.1 may include ramped or rounded edges which are adapted to engage a circumferential collar 5.2 disposed on a proximal opening of thesyringe body 5. In a non-deflected state, a first diameter of the resilient flanges 18.1 is larger than a second diameter of a proximal opening of thesyringe body 5. When theplunger 18 initially contacts thesyringe body 5, the flanges 18.1 abut the collar 5.2 and push the syringe carrier (and thesyringe 4 therein) distally relative to thecase 2 until the syringe carrier is stopped (e.g., against thecase 2 or a distal stop positioned in the case 2) which results in insertion of theneedle 7 through aperture 3.1 into the injection site. After needle insertion, the flanges 18.1 transition to a deflected state, allowing theplunger 18 to enter thesyringe body 5 and push the stopper 19 to dispense the medicament. - In an exemplary embodiment, a
retraction spring 28 biases the syringe carrier in a retracted position in thecase 2. Thus, as theplunger 18 advances the syringe carrier distally, theretraction spring 28 is compressed. In an exemplary embodiment, the retraction spring bears on the syringe carrier. In another exemplary embodiment, theretraction spring 28 may bear on a rib 6.1 formed on thesyringe case 6. In the latter exemplary embodiment, theautoinjector 1 may not utilize a syringe carrier, but include a channel adapted to receive thesyringe 4. A proximal stop may be positioned in thecase 2 to prevent the syringe carrier from moving proximally beyond the retracted position. - In an exemplary embodiment, the
autoinjector 1 includes adata processing unit 13 which controls operation of theautoinjector 1. Thedata processing unit 13 may include a microprocessor and memory. As described further herein, thedata processing unit 13 may process/store data and control operation of theautoinjector 1. For example, thedata processing unit 13 may read data from and/or write data to thedata storage device 11 on thesyringe 4. - In an exemplary embodiment, at least one encoder is utilized to provide a data signal to the
data processing unit 13 which is used to determine a position of theplunger 18. The encoder may be optical, mechanical, magnetic, etc. to detect a position of theplunger 18. In another exemplary embodiment, the encoder may be disposed on thedrive gear 20 to sense angular rotation, and thedata processing unit 13 may determine a position of theplunger 18 may on the rotation data. - As shown in
FIGS. 7 and 8 , an exemplary embodiment of theautoinjector 1 may include aboot removal mechanism 29 for removing theneedle boot 8 from theneedle 7. In an exemplary embodiment, theboot removal mechanism 29 comprises agear 30 which mates with arack 31 disposed in thecase 2. Thegear 30 is rotated by the closing of thedoor 22. When thedoor 22 is closed, thegear 30 rotates, causing therack 31 to advance in the proximal direction and compressing aboot removal spring 26. Resilient locking beams 32 coupled to therack 31 are advanced over theneedle boot 8 until hooks on thelocking beam 32 engage a proximal end of theneedle boot 8. The locking beams 32 may be retained in this position by a solenoid. Prior to an injection, the solenoid is discharged to release the locking beams 32, which under the biasing force of theboot removal spring 26, push theneedle boot 8 off of theneedle 7 and at least partially through the aperture 3.1 (so the user can manually remove theneedle boot 8 completely). Those of skill in the art will understand that theboot removal mechanism 29 may be configured for completely removing theneedle boot 8 from the needle 7 (e.g., by using a more powerful boot removal spring 26). - In an exemplary embodiment, the
autoinjector 1 comprises a user interface which may include visual and acoustic components, such as LEDs, a display, atouch screen 14, a speaker, a microphone, buttons, dials, switches, etc. Thedata processing unit 13 may, for example, provide visual/audible cues to guide the user through an injection process, alert that a patient is due for an injection, provide distraction and/or re-assurance during the injection, providing data about the medicament (e.g., obtained from the data storage device 11), etc. - Further, the user interface may, for example, be used to configure a patient profile, configure insertion depth, injection speed, and medicament type, provide user feedback of comfort in injection, display instructions on loading or reloading of a
syringe 4, authenticate a user, provide visual/audio/vibration feedback to the user to indicate injection progress, injection completion, historical user data, drug properties (e.g. use by date), etc. - In an exemplary embodiment, the user interface includes a
trigger button 16 disposed on thecase 2 for activating the injection process. - In an exemplary embodiment, a heater/cooling device (not illustrated) may be arranged within the
case 2 for heating or cooling the medicament. -
FIG. 12 shows an exemplary embodiment of asensor arrangement 27 for use with theautoinjector 1 according to the present invention. In an exemplary embodiment, thesensor arrangement 27 is arranged in or behind thecontact surface 3 for detecting veins, scar tissue, detecting contact with the injection site, and/or detecting an angle of theneedle 7 with respect to the injection site. In an exemplary embodiment, thesensor arrangement 27 comprises at least one near infrared LED 27.1, a projector 27.2 and a camera 27.3. The near infrared LEDs 27.1 are arranged to illuminate the injection site, and the camera 27.3 may then obtain an image of the injection site to determine whether veins or scars are present, which would indicate an undesirable injection site. The camera 27.3 may be arranged as an integrated image sensor and lens. The projector 27.2 may comprise a laser and a diffractive optical element arranged to project aplanar grid 33 onto the injection site which may be detected by the camera 27.3. Orientation of theautoinjector 1 relative to the injection site and/or injection site abnormalities may be determined from a distortion of thegrid 33 detected by the camera 27.3. For example,FIGS. 13 and 14 show exemplary embodiments of thegrid 33 indicating a relatively flat injection site surface (FIG. 13 ) and contoured injection site surface (FIG. 14 ), the latter of which may be undesirable for an injection. - An exemplary sequence of operation for the
autoinjector 1 may be as follows: - The
autoinjector 1 may provide an injection alert (e.g., based on a treatment protocol schedule) indicating it is time to administer an injection. The user interface may provide various details about the injection, e.g., day/time of last injection, medicament to inject, day/time for a subsequent injection, etc. In an exemplary embodiment, theautoinjector 1 may remain in a low-power or “sleep” mode until it provides the injection alert or is manually activated by a user. - When the
autoinjector 1 is activated, thedoor 22 is opened and asyringe 4 is placed in the syringe carrier. As thedoor 22 is closed, theboot removal mechanism 29 is operated to engage theneedle boot 8 on thesyringe 4. After thedoor 22 is closed, thedoor latch 25 may lock thedoor 22 in the closed position. - When the
door 22 is closed and locked, thedata processing unit 13 may perform various functions such as, for example, authenticating the syringe 4 (via data on the data storage device 11), detecting medicament conditions (e.g., temperature, expiry date, etc.), and initializing mechanical, electronic and optical components of theautoinjector 1 to ensure that all are in working conditions. - In an exemplary embodiment, if the medicament is not a proper injection temperature, the heater/cooling device may heat/cool the medicament as appropriate.
- The user interface may notify the user when the
autoinjector 1 is ready for the injection. If, for example, the user presses the trigger button 16 a first time, the solenoid of theboot removal mechanism 29 may be discharged, and theneedle boot 8 may be at least partially disengaged from theneedle 7 and presented through the aperture 3.1. The user may then remove theneedle boot 8, while maintaining needle safety, because theneedle 7 remains fully enclosed by thecase 2. - When the
autoinjector 1 is positioned on an injection site, thesensor arrangement 27 may provide various information to thedata processing unit 13 to determine if the injection site is adequate (e.g., aligned properly, no veins/scars detected, relatively flat surface, etc.). - As shown in
FIG. 10 , theautoinjector 1 is ready for the injection. When, for example, the user presses thetrigger button 16, themotor 15 rotates thedrive gear 20 to rotate and advance theplunger 18. The resilient flange 18.1 of the plunger engages the proximal collar 5.2 of thesyringe body 5 and pushes the syringe 4 (and/or the syringe carrier) in the distal direction, compressing theretraction spring 28. When the syringe carrier abuts a distal stop in thecase 2, theneedle 7 is extended through the aperture 3.1 and inserted into the injection site. - When the syringe carrier abuts the distal stop, the continued rotation of the
drive gear 20 causes the resilient flange 18.1 to deflect, allowing theplunger 18 to enter thesyringe body 5 and engage the stopper 19. Theplunger 18 pushes the stopper 19 distally within thesyringe body 5 to dispense the medicament through theneedle 7, as shown inFIG. 11 . - After the medicament has been dispensed, the
motor 15 may release tension on thedrive gear 20, allowing the force of theretraction spring 28 to push the syringe carrier in the proximal direction to withdraw theneedle 7 from the injection site. In another exemplary embodiment, themotor 15 may reverse and rotate thedrive gear 20 in an opposite rotational direction to withdraw force on the syringe carrier. In another exemplary embodiment, thedrive gear 20 may disengage themotor 15, releasing force on the syringe carrier. - In an exemplary embodiment, as the
needle 7 is withdrawn from the injection site, theneedle shield 9 on thesyringe 4 may be deployed under the force of thespring 10. For example, when thesyringe 4 is at penetration depth, a latch on theneedle shield 9 may be disengaged and allow thespring 10 to push theneedle shield 9. However, during medicament delivery, theneedle shield 9 may abut the distal end of thecase 2. As thesyringe 4 is retracted, theneedle shield 9 may fully deploy to the extended position covering theneedle 7. In an exemplary embodiment, theretraction spring 28 may push the syringe 4 a sufficient distance in the proximal direction to ensure that theneedle shield 9 can achieve the extended position. - When the injection is complete, the
door 22 may be opened and the usedsyringe 4 may be removed. Because theneedle shield 9 is in the extended position, theneedle 7 is fully covered, significantly reducing the risk of needle stick injuries. - Throughout the injection process, the
autoinjector 1 may continuously monitor its status and provide feedback/instructions to the user via the user interface. For example, thedata processing unit 13 may monitor position of theplunger 13, contact between theautoinjector 1 and the injection site, etc. For example, on detection of premature removal of theautoinjector 1 from the injection site, theautoinjector 1 may be controlled to immediately stop dispensing the drug and retract theneedle 7. Controlling the needle insertion speed, dispense rate and needle insertion depth may improve patient comfort and compliance with a treatment protocol. - Those of skill in the art will understand that modifications (additions and/or removals) of various components of the apparatuses, methods and/or systems and embodiments described herein may be made without departing from the full scope and spirit of the present invention, which encompass such modifications and any and all equivalents thereof.
Claims (21)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/542,964 US20190365998A1 (en) | 2012-08-15 | 2019-08-16 | Autoinjector |
US18/404,205 US20240226437A9 (en) | 2012-08-15 | 2024-01-04 | Autoinjector |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12180577.4A EP2698180A1 (en) | 2012-08-15 | 2012-08-15 | Autoinjector |
EP12180577.4 | 2012-08-15 | ||
PCT/EP2013/066775 WO2014026937A1 (en) | 2012-08-15 | 2013-08-12 | Autoinjector |
US201514421020A | 2015-02-11 | 2015-02-11 | |
US16/542,964 US20190365998A1 (en) | 2012-08-15 | 2019-08-16 | Autoinjector |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2013/066775 Continuation WO2014026937A1 (en) | 2012-08-15 | 2013-08-12 | Autoinjector |
US14/421,020 Continuation US10413667B2 (en) | 2012-08-15 | 2013-08-12 | Autoinjector |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US18/404,205 Continuation US20240226437A9 (en) | 2012-08-15 | 2024-01-04 | Autoinjector |
Publications (1)
Publication Number | Publication Date |
---|---|
US20190365998A1 true US20190365998A1 (en) | 2019-12-05 |
Family
ID=48986107
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/421,020 Active 2036-02-29 US10413667B2 (en) | 2012-08-15 | 2013-08-12 | Autoinjector |
US16/542,964 Abandoned US20190365998A1 (en) | 2012-08-15 | 2019-08-16 | Autoinjector |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/421,020 Active 2036-02-29 US10413667B2 (en) | 2012-08-15 | 2013-08-12 | Autoinjector |
Country Status (7)
Country | Link |
---|---|
US (2) | US10413667B2 (en) |
EP (2) | EP2698180A1 (en) |
JP (1) | JP6215939B2 (en) |
CN (1) | CN104703641B (en) |
DK (1) | DK2885025T3 (en) |
HK (1) | HK1207998A1 (en) |
WO (1) | WO2014026937A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023287868A1 (en) * | 2021-07-13 | 2023-01-19 | Becton, Dickinson And Company | System to detect markers of a lipohypertrophy lesion |
Families Citing this family (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8157769B2 (en) | 2009-09-15 | 2012-04-17 | Medimop Medical Projects Ltd. | Cartridge insertion assembly for drug delivery system |
EP2915157B1 (en) | 2012-10-30 | 2019-05-08 | Truinject Corp. | System for injection training |
TWI569832B (en) | 2013-10-23 | 2017-02-11 | 卡貝歐洲有限公司 | Medicament delivery device |
CA3098401C (en) * | 2013-12-04 | 2023-05-09 | Becton, Dickinson And Company | Systems, apparatuses and methods to encourage injection site rotation and prevent lipodystrophy from repeated injections to a body area |
EP3111438B1 (en) | 2014-01-17 | 2018-12-19 | Truinject Medical Corp. | Injection site training system |
US10290231B2 (en) | 2014-03-13 | 2019-05-14 | Truinject Corp. | Automated detection of performance characteristics in an injection training system |
CA2949846C (en) | 2014-06-03 | 2023-09-05 | Amgen Inc. | Devices and methods for assisting a user of a drug delivery device |
CA2952167C (en) | 2014-06-13 | 2023-06-13 | Aterica Inc. | System and device for management of medication delivery devices |
US10773028B2 (en) * | 2014-10-07 | 2020-09-15 | Silgan Dispensing Systems Corporation | Indexing dose dispensing device |
KR20170102233A (en) | 2014-12-01 | 2017-09-08 | 트루인젝트 코프 | Injection training tool emitting omnidirectional light |
AU2015372441A1 (en) | 2014-12-23 | 2017-08-10 | Automed Pty Ltd | Delivery apparatus, system and associated methods |
US10182969B2 (en) | 2015-03-10 | 2019-01-22 | Regeneron Pharmaceuticals, Inc. | Aseptic piercing system and method |
EP4252798A3 (en) | 2015-06-04 | 2023-10-25 | Medimop Medical Projects Ltd. | Cartridge insertion for drug delivery device |
US10500340B2 (en) | 2015-10-20 | 2019-12-10 | Truinject Corp. | Injection system |
WO2017086924A1 (en) * | 2015-11-17 | 2017-05-26 | Monti Jr James | Integrated fluid administration system |
WO2017087888A1 (en) | 2015-11-18 | 2017-05-26 | President And Fellows Of Harvard College | Systems and methods for monitoring, managing, and treating asthma and anaphylaxis |
US11285268B2 (en) | 2016-01-06 | 2022-03-29 | Sanofi-Aventis Deutschland Gmbh | Medicament delivery device |
WO2017151441A2 (en) | 2016-02-29 | 2017-09-08 | Truinject Medical Corp. | Cosmetic and therapeutic injection safety systems, methods, and devices |
US10648790B2 (en) | 2016-03-02 | 2020-05-12 | Truinject Corp. | System for determining a three-dimensional position of a testing tool |
WO2017151963A1 (en) | 2016-03-02 | 2017-09-08 | Truinject Madical Corp. | Sensory enhanced environments for injection aid and social training |
WO2017165154A1 (en) * | 2016-03-21 | 2017-09-28 | Eli Lilly And Company | Medical delivery device with axially expandable drive member |
GB2549750A (en) * | 2016-04-27 | 2017-11-01 | Owen Mumford Ltd | Medicament delivery device |
US10376656B2 (en) * | 2016-05-18 | 2019-08-13 | Portal Instruments, Inc. | Side-angle decapping of pre-filled syringe |
JP6957525B2 (en) | 2016-06-02 | 2021-11-02 | ウェスト ファーマ サービシーズ イスラエル リミテッド | Needle evacuation by 3 positions |
JP7059251B2 (en) * | 2016-08-01 | 2022-04-25 | ウェスト ファーマ サービシーズ イスラエル リミテッド | A spring that prevents the door from closing halfway |
CN106236317A (en) * | 2016-08-26 | 2016-12-21 | 中国科学院深圳先进技术研究院 | A kind of trace injection instrument |
CA2940544A1 (en) * | 2016-08-29 | 2018-02-28 | Duoject Medical Systems Inc. | Auto-injector |
CN110545861B (en) | 2017-01-17 | 2022-07-26 | 西部制药服务有限公司(以色列) | Curved spring powered injector |
WO2018136901A1 (en) | 2017-01-23 | 2018-07-26 | Truinject Corp. | Syringe dose and position measuring apparatus |
US20180263747A1 (en) | 2017-03-14 | 2018-09-20 | Desvac | Apparatus and method for a single sensor action plate |
US10772715B2 (en) * | 2017-04-25 | 2020-09-15 | Digirodeo S.A. | Injection pistol for animal treatment with identification assistant |
CN107013112A (en) * | 2017-05-01 | 2017-08-04 | 成都爱可信科技有限公司 | A kind of smart electronicses pin puts handcuffs on system |
EA201992189A1 (en) * | 2017-05-05 | 2020-03-06 | Ридженерон Фармасьютикалз, Инк. | AUTOMATIC MEDICAL SYRINGE |
WO2018222521A1 (en) | 2017-05-30 | 2018-12-06 | West Pharma. Services IL, Ltd. | Modular drive train for wearable injector |
CN107441594B (en) * | 2017-08-16 | 2023-07-14 | 重庆中电大宇卫星应用技术研究所有限公司 | Full-automatic painless injection device |
EP3697472A1 (en) * | 2017-10-19 | 2020-08-26 | Sanofi | A medicament administration device and data collection device |
US10909830B1 (en) * | 2017-11-07 | 2021-02-02 | Pica Product Development, Llc | Personal emergency alert system, method and device |
US10798541B2 (en) | 2017-11-07 | 2020-10-06 | Pica Product Development, Llc | Systems, methods and devices for remote trap monitoring |
US10694338B2 (en) | 2017-11-07 | 2020-06-23 | Pica Product Development, Llc | Cellular automated external defibrillator (AED) tracker |
IL310135A (en) * | 2017-12-08 | 2024-03-01 | Lilly Co Eli | Medical delivery device with axially expandable drive ribbon |
EP3727516A1 (en) | 2017-12-19 | 2020-10-28 | Biocorp Production S.A. | Auto-injection drug delivery device |
US11857767B2 (en) | 2017-12-22 | 2024-01-02 | West Pharma. Services IL, Ltd. | Injector usable with different dimension cartridges |
WO2019133648A1 (en) | 2017-12-29 | 2019-07-04 | Genentech, Inc. | Injection monitoring device with delivery signature |
US10905821B2 (en) * | 2018-07-11 | 2021-02-02 | Flex, Ltd. | Capacitor detection for IV pump tube calibration |
US11504469B2 (en) | 2018-07-11 | 2022-11-22 | Flex Ltd. | Reed switch detection for IV pump tube calibration |
US10898640B2 (en) * | 2018-07-11 | 2021-01-26 | Flex, Ltd. | Visual detection for IV pump tube calibration |
GB2577682B (en) * | 2018-09-28 | 2021-10-20 | Owen Mumford Ltd | Auto-injector |
GB2578129A (en) * | 2018-10-17 | 2020-04-22 | My Invu Ltd | Injection apparatus |
EP3666314A1 (en) * | 2018-12-10 | 2020-06-17 | Ares Trading S.A. | Injection device |
US11806511B2 (en) * | 2019-03-13 | 2023-11-07 | Amana Fujikawa | Auto injector device |
EP3983031A1 (en) * | 2019-06-12 | 2022-04-20 | SHL Medical AG | Drive mechanism for a medicament delivery device |
MX2022001112A (en) * | 2019-08-01 | 2022-02-16 | Amgen Inc | Drug delivery device with temperature measurement and related method. |
US20230001100A1 (en) * | 2019-11-21 | 2023-01-05 | Ishai Ben David | Liquid delivery device and method |
US11957542B2 (en) | 2020-04-30 | 2024-04-16 | Automed Patent Holdco, Llc | Sensing complete injection for animal injection device |
CN113029727A (en) * | 2021-04-26 | 2021-06-25 | 常州大学 | Adhesion testing device capable of forming regular spherical hydrate particles |
USD1007676S1 (en) | 2021-11-16 | 2023-12-12 | Regeneron Pharmaceuticals, Inc. | Wearable autoinjector |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4493704A (en) * | 1982-11-29 | 1985-01-15 | Oximetrix, Inc. | Portable fluid infusion apparatus |
US20110004165A1 (en) * | 2008-04-10 | 2011-01-06 | Toshiaki Iio | Medication administering device |
WO2011108225A1 (en) * | 2010-03-01 | 2011-09-09 | パナソニック株式会社 | Medicine administering device |
US20130245545A1 (en) * | 2011-09-20 | 2013-09-19 | Medingo Ltd. | Drug Injection Devices, Systems and Methods |
US20130274655A1 (en) * | 2010-12-21 | 2013-10-17 | Douglas Jennings | Auto-injector |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3388863A (en) | 1966-10-20 | 1968-06-18 | Gen Ind Equipment Company | Air-conditioning device for controlling humidity and temperature |
BE755224A (en) * | 1969-08-25 | 1971-02-24 | Philips Nv | INJECTION SYRINGE |
US3712301A (en) * | 1971-01-11 | 1973-01-23 | Survival Technology | Gun type hypodermic injector with rapid cartridge displacement within holder |
US3882863A (en) | 1973-08-01 | 1975-05-13 | Survival Technology | Hypodermic injection device having cannula covered with resilient sheath |
PL330757A1 (en) * | 1996-07-05 | 1999-05-24 | Novo Nordisk As | Elastic piston rod |
US6585699B2 (en) | 2000-04-13 | 2003-07-01 | Nna/S | Drug delivery device provided with a one-way mechanism |
GB0107600D0 (en) * | 2001-03-27 | 2001-05-16 | Dca Design Int Ltd | Improvements in and relating to an injection device |
US20030105430A1 (en) * | 2001-11-30 | 2003-06-05 | Elan Pharma International Limited Wil House | Automatic injector |
DE10240166A1 (en) * | 2002-08-30 | 2004-03-18 | Disetronic Licensing Ag | Injection syringe for dispensing insulin to treat diabetes has piston operated by flexible belt which is moved by manually-operated wheel with teeth which cooperate with catches set to give predetermined dose |
ATE498421T1 (en) * | 2002-12-23 | 2011-03-15 | Asante Solutions Inc | FLEXIBLE PISTON ROD |
CA2767916C (en) | 2004-02-18 | 2014-04-15 | Ares Trading S.A. | Hand-held electronically controlled injection device for injecting liquid medications |
GB0414054D0 (en) | 2004-06-23 | 2004-07-28 | Owen Mumford Ltd | Improvements relating to automatic injection devices |
WO2006065271A2 (en) * | 2004-12-15 | 2006-06-22 | Embo-Optics, Llc | Point of infusion lighting device |
US8478386B2 (en) | 2006-01-10 | 2013-07-02 | Accuvein Inc. | Practitioner-mounted micro vein enhancer |
US8702654B2 (en) * | 2009-03-25 | 2014-04-22 | John M. Agee | Treatment of carpal tunnel syndrome by injection of the flexor retinaculum |
EP2238999A1 (en) * | 2009-04-02 | 2010-10-13 | Vincent Pongpairochana | Automatic injection device |
US9457150B2 (en) * | 2009-06-01 | 2016-10-04 | Sanofi-Aventis Deutschland Gmbh | Biasing mechanism for a drug delivery device |
EP2608825B1 (en) * | 2010-08-27 | 2014-08-13 | Novo Nordisk A/S | Medical injection device |
US9192716B2 (en) * | 2011-03-16 | 2015-11-24 | Sanofi-Aventis Deutschland Gmbh | Drive mechanism for a drug delivery device and drug delivery device |
-
2012
- 2012-08-15 EP EP12180577.4A patent/EP2698180A1/en not_active Ceased
-
2013
- 2013-08-12 CN CN201380053063.7A patent/CN104703641B/en active Active
- 2013-08-12 DK DK13750017.9T patent/DK2885025T3/en active
- 2013-08-12 WO PCT/EP2013/066775 patent/WO2014026937A1/en active Application Filing
- 2013-08-12 US US14/421,020 patent/US10413667B2/en active Active
- 2013-08-12 EP EP13750017.9A patent/EP2885025B1/en active Active
- 2013-08-12 JP JP2015526950A patent/JP6215939B2/en active Active
-
2015
- 2015-09-02 HK HK15108568.8A patent/HK1207998A1/en unknown
-
2019
- 2019-08-16 US US16/542,964 patent/US20190365998A1/en not_active Abandoned
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4493704A (en) * | 1982-11-29 | 1985-01-15 | Oximetrix, Inc. | Portable fluid infusion apparatus |
US20110004165A1 (en) * | 2008-04-10 | 2011-01-06 | Toshiaki Iio | Medication administering device |
WO2011108225A1 (en) * | 2010-03-01 | 2011-09-09 | パナソニック株式会社 | Medicine administering device |
US20120323176A1 (en) * | 2010-03-01 | 2012-12-20 | Atsushi Watanabe | Pharmaceutical injection device |
US20130274655A1 (en) * | 2010-12-21 | 2013-10-17 | Douglas Jennings | Auto-injector |
US20130245545A1 (en) * | 2011-09-20 | 2013-09-19 | Medingo Ltd. | Drug Injection Devices, Systems and Methods |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023287868A1 (en) * | 2021-07-13 | 2023-01-19 | Becton, Dickinson And Company | System to detect markers of a lipohypertrophy lesion |
Also Published As
Publication number | Publication date |
---|---|
JP2015524722A (en) | 2015-08-27 |
WO2014026937A1 (en) | 2014-02-20 |
US20240131264A1 (en) | 2024-04-25 |
CN104703641A (en) | 2015-06-10 |
EP2885025A1 (en) | 2015-06-24 |
HK1207998A1 (en) | 2016-02-19 |
US20150290392A1 (en) | 2015-10-15 |
EP2698180A1 (en) | 2014-02-19 |
DK2885025T3 (en) | 2022-08-01 |
CN104703641B (en) | 2017-10-10 |
EP2885025B1 (en) | 2022-05-11 |
JP6215939B2 (en) | 2017-10-18 |
US10413667B2 (en) | 2019-09-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20190365998A1 (en) | Autoinjector | |
US20230347054A1 (en) | Autoinjector | |
DK3019220T3 (en) | autoinjector | |
US10737019B2 (en) | Injection system | |
JP2015524722A5 (en) | ||
DK2661292T3 (en) | SAFETY DEVICE FOR A PRELIMINARY Syringe and Injection Device | |
EP3384944A1 (en) | Auto-injector | |
DK3019215T3 (en) | autoinjector | |
EP3019218A1 (en) | Autoinjector | |
EP3065800A1 (en) | Injection device | |
US9597452B2 (en) | Autoinjector | |
EP2762184A1 (en) | Drive arrangement for drug dispense device | |
EP2866860B1 (en) | Autoinjector | |
US20240226437A9 (en) | Autoinjector |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
AS | Assignment |
Owner name: SANOFI-AVENTIS DEUTSCHLAND GMBH, GERMANY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:HENDERSON, CHARLEY;CROSS, DAVID;JENNINGS, DOUGLAS;AND OTHERS;SIGNING DATES FROM 20130923 TO 20131014;REEL/FRAME:054668/0860 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE AFTER FINAL ACTION FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |